ANZ
DATA

**AUSTRALIA &
NEW ZEALAND**
DIALYSIS & TRANSPLANT
REGISTRY

MISSING DATA REPORT

Survey Data 2014 – 2018

Abstract

The rates of non-response for ANZDATA survey items over the last 5 years

ANZDATA Registry
anzdata@anzdata.org.au

Contents

Version Control

Version #	Release Date	Description of Release
Version 1.0	3rd September, 2019	*Initial version release post analysis lock date (30th August, 2019)*
Version 2.0	23rd September, 2019	*Table 15 - Transplant Baseline Data, page 7 - Updated numbers of CMV, EBV, Immediate Function and Ischaemic Time due to late reported data from Alfred Hospital (Victoria), Prince of Wales and Westmead Hospitals (New South Wales).*

The tables shown here present the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Patient Details

Table 1 Demographics

Variable	2014	2015	2016	2017	2018
Frequency	3354	3334	3508	3723	3738
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	53 (1.6%)	71 (2.1%)	108 (3.1%)	58 (1.6%)	69 (1.8%)
Late referral seen <3 mths before 1st treatment	73 (2.2%)	135 (4.0%)	158 (4.5%)	73 (2.0%)	80 (2.1%)
Racial origin	64 (1.9%)	96 (2.9%)	167 (4.8%)	66 (1.8%)	124 (3.3%)
Primary renal disease	25 (0.7%)	104 (3.1%)	139 (4.0%)	64 (1.7%)	71 (1.9%)
Was native kidney biopsied?	70 (2.1%)	132 (4.0%)	230 (6.6%)	109 (2.9%)	88 (2.4%)
Serum creatinine at entry	73 (2.2%)	130 (3.9%)	141 (4.0%)	86 (2.3%)	89 (2.4%)
Height at RRT entry (cm)	96 (2.9%)	124 (3.7%)	196 (5.6%)	130 (3.5%)	137 (3.7%)
Weight at RRT entry (kg)	55 (1.6%)	68 (2.0%)	125 (3.6%)	63 (1.7%)	70 (1.9%)
Smoking status at RRT entry	18 (0.5%)	121 (3.6%)	177 (5.0%)	119 (3.2%)	107 (2.9%)

Table 2 Comorbidities at RRT entry

Variable	2014	2015	2016	2017	2018
Frequency	3354	3334	3508	3723	3738
Postcode	532 (15.9%)	398 (11.9%)	194 (5.5%)	69 (1.9%)	80 (2.1%)
Chronic lung disease	16 (0.5%)	25 (0.7%)	77 (2.2%)	55 (1.5%)	6 (0.2%)
Coronary artery disease	17 (0.5%)	26 (0.8%)	75 (2.1%)	56 (1.5%)	6 (0.2%)
Peripheral vascular disease	16 (0.5%)	27 (0.8%)	75 (2.1%)	55 (1.5%)	6 (0.2%)
Cerebrovascular disease	15 (0.4%)	25 (0.7%)	74 (2.1%)	54 (1.5%)	6 (0.2%)
Diabetes	15 (0.4%)	22 (0.7%)	67 (1.9%)	47 (1.3%)	6 (0.2%)

Table 3 Comorbidities at survey date

Variable	2014	2015	2016	2017	2018
Frequency	29853	30878	31933	33153	34251
Postcode	4878 (16.3%)	3051 (9.9%)	1173 (3.7%)	389 (1.2%)	463 (1.4%)
Chronic lung disease	86 (0.3%)	127 (0.4%)	143 (0.4%)	143 (0.4%)	55 (0.2%)
Coronary artery disease	84 (0.3%)	125 (0.4%)	145 (0.5%)	139 (0.4%)	54 (0.2%)
Peripheral vascular disease	85 (0.3%)	125 (0.4%)	145 (0.5%)	142 (0.4%)	55 (0.2%)
Cerebrovascular disease	86 (0.3%)	126 (0.4%)	148 (0.5%)	143 (0.4%)	56 (0.2%)
Diabetes	92 (0.3%)	137 (0.4%)	146 (0.5%)	126 (0.4%)	54 (0.2%)
Hepatitis C Antibody	73 (0.2%)	150 (0.5%)	225 (0.7%)	195 (0.6%)	243 (0.7%)

Course of Treatment

Table 4 Reason for change from CAPD to APD

Variable	2014	2015	2016	2017	2018
Frequency	658	702	610	623	638
Reason transfer from dialysis during survey	49 (7.4%)	50 (7.1%)	58 (9.5%)	44 (7.1%)	49 (7.7%)

Table 5 Reason for change from APD to CAPD

Variable	2014	2015	2016	2017	2018
Frequency	114	127	118	141	79
Reason transfer from dialysis during survey	10 (8.8%)	14 (11.0%)	17 (14.4%)	17 (12.1%)	4 (5.1%)

Table 6 Reason for change from PD to HD

Variable	2014	2015	2016	2017	2018
Frequency	731	843	838	807	800
Reason transfer from dialysis during survey	49 (6.7%)	74 (8.8%)	96 (11.5%)	55 (6.8%)	49 (6.1%)

Table 7 Reason for change from HD to PD

Variable	2014	2015	2016	2017	2018
Frequency	582	546	539	554	518
Reason transfer from dialysis during survey	48 (8.2%)	48 (8.8%)	71 (13.2%)	41 (7.4%)	38 (7.3%)

Table 8 Cause of death

Variable	2014	2015	2016	2017	2018
Frequency	2304	2439	2555	2681	2536
Cause of death	1 (0.0%)	2 (0.1%)	21 (0.8%)	108 (4.0%)	55 (2.2%)

Dialysis Data

Table 9 Dialysis data

Variable	2014	2015	2016	2017	2018
Frequency	18027	18518	18991	19427	19729
Dialysis type	312 (1.7%)	280 (1.5%)	201 (1.1%)	93 (0.5%)	751 (3.8%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	806 (4.5%)	1165 (6.3%)	1644 (8.7%)	893 (4.6%)	801 (4.1%)
Uncorrected calcium levels (mmol/l)	730 (4.0%)	1131 (6.1%)	1516 (8.0%)	823 (4.2%)	781 (4.0%)
Phosphate levels (mmol/l)	665 (3.7%)	1071 (5.8%)	1488 (7.8%)	804 (4.1%)	752 (3.8%)
Haemoglobin level nearest end Survey (g/l)	654 (3.6%)	1064 (5.7%)	1483 (7.8%)	819 (4.2%)	755 (3.8%)
EPO Agent	643 (3.6%)	1044 (5.6%)	1516 (8.0%)	832 (4.3%)	751 (3.8%)
Ferritin within last 3 months of Survey	1603 (8.9%)	1884 (10.2%)	2649 (13.9%)	1926 (9.9%)	1768 (9.0%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	2121 (11.8%)	2378 (12.8%)	3283 (17.3%)	2313 (11.9%)	2354 (11.9%)

Table 10 Haemodialysis data

Variable	2014	2015	2016	2017	2018
Frequency	14469	14880	15348	15759	16080
Dialyser brand, model, membrane, surface area	625 (4.3%)	960 (6.5%)	1060 (6.9%)	729 (4.6%)	652 (4.1%)
Blood flow rate (mls/min)	636 (4.4%)	958 (6.4%)	1330 (8.7%)	729 (4.6%)	663 (4.1%)
Frequency of dialysis per week	614 (4.2%)	942 (6.3%)	1304 (8.5%)	703 (4.5%)	625 (3.9%)
Hours per session	618 (4.3%)	946 (6.4%)	1324 (8.6%)	727 (4.6%)	654 (4.1%)
Adequacy method (urea reduction or Kt/V)	2603 (18.0%)	2811 (18.9%)	3513 (22.9%)	2902 (18.4%)	2858 (17.8%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	2705 (18.7%)	2844 (19.1%)	3399 (22.1%)	2923 (18.5%)	2858 (17.8%)
Vascular access in use at last haemodialysis	666 (4.6%)	1024 (6.9%)	1367 (8.9%)	749 (4.8%)	675 (4.2%)

Table 11 Access at first HD

Variable	2014	2015	2016	2017	2018
Frequency	2680	2735	2891	3072	3090
Vascular access in use at first haemodialysis	138 (5.1%)	225 (8.2%)	228 (7.9%)	101 (3.3%)	81 (2.6%)

Table 12 Peritoneal dialysis data

Variable	2014	2015	2016	2017	2018
Frequency	4627	4768	4784	4784	4746
Type of Peritoneal Connection System	214 (4.6%)	397 (8.3%)	409 (8.5%)	252 (5.3%)	304 (6.4%)
Total volume weekly exchanges - All PD	219 (4.7%)	368 (7.7%)	569 (11.9%)	246 (5.1%)	213 (4.5%)
PD Solution Glucose	199 (4.3%)	351 (7.4%)	443 (9.3%)	242 (5.1%)	204 (4.3%)
PD Solution Iodextrin	202 (4.4%)	357 (7.5%)	441 (9.2%)	243 (5.1%)	203 (4.3%)
PD Solution Low GDP (either Lactate or Bicarbonate)	208 (4.5%)	372 (7.8%)	442 (9.2%)	239 (5.0%)	206 (4.3%)
Creatinine Clearance (litres per week)	1399 (30.2%)	1648 (34.6%)	1793 (37.5%)	1574 (32.9%)	1473 (31.0%)
Dialysate Only Weekly Kt/V value on PD	1404 (30.3%)	1650 (34.6%)	1793 (37.5%)	1564 (32.7%)	1482 (31.2%)
Residual renal function (creatinine clearance - GFR)	1442 (31.2%)	1706 (35.8%)	1827 (38.2%)	1608 (33.6%)	1488 (31.4%)

Table 13 Peritoneal dialysis PET test

Variable	2014	2015	2016	2017	2018
Frequency	1383	1354	1391	1406	1370
PET test for PD-within first 6 mths starting?	1170 (84.6%)	1255 (92.7%)	1324 (95.2%)	1306 (92.9%)	1180 (86.1%)

Table 14 Peritonitis episodes data

Variable	2014	2015	2016	2017	2018
Frequency	1116	1157	1091	1072	1080
Was this a relapse or recurrence of peritonitis?	195 (17.5%)	113 (9.8%)	150 (13.7%)	131 (12.2%)	49 (4.5%)
Technique at time of infection	190 (17.0%)	64 (5.5%)	62 (5.7%)	52 (4.9%)	18 (1.7%)
Antifungal Therapy?	228 (20.4%)	147 (12.7%)	182 (16.7%)	158 (14.7%)	52 (4.8%)
Name of initial regimen first antibiotic given	190 (17.0%)	122 (10.5%)	143 (13.1%)	130 (12.1%)	43 (4.0%)
Name of final regimen first antibiotic given	239 (21.4%)	154 (13.3%)	169 (15.5%)	148 (13.8%)	113 (10.5%)
Glucose PD Solution at time of infection?	215 (19.3%)	186 (16.1%)	200 (18.3%)	177 (16.5%)	91 (8.4%)
Icodextrin PD Solution at time of infection?	226 (20.3%)	191 (16.5%)	210 (19.2%)	179 (16.7%)	91 (8.4%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	232 (20.8%)	168 (14.5%)	197 (18.1%)	196 (18.3%)	111 (10.3%)
Was patient hospitalised overnight?	207 (18.5%)	128 (11.1%)	151 (13.8%)	129 (12.0%)	46 (4.3%)
Was catheter removed?	193 (17.3%)	118 (10.2%)	154 (14.1%)	123 (11.5%)	55 (5.1%)
Did patient have interim haemodialysis?	211 (18.9%)	131 (11.3%)	169 (15.5%)	144 (13.4%)	76 (7.0%)
Did patient transfer to permanent haemodialysis?	206 (18.5%)	127 (11.0%)	164 (15.0%)	145 (13.5%)	80 (7.4%)

Transplant Data

Table 15 Transplant baseline data

Variable	2014	2015	2016	2017	2018
Frequency	1041	1092	1257	1290	1317
Recipient CMV antibody status	41 (3.9%)	52 (4.8%)	132 (10.5%)	59 (4.6%)	18 (1.4%)
Recipient EBV antibody status	44 (4.2%)	58 (5.3%)	141 (11.2%)	57 (4.4%)	19 (1.4%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	72 (6.9%)	67 (6.1%)	147 (11.7%)	83 (6.4%)	37 (2.8%)
Immediate function	38 (3.7%)	40 (3.7%)	119 (9.5%)	38 (2.9%)	25 (1.9%)
HLA-A mismatch	35 (3.4%)	23 (2.1%)	24 (1.9%)	23 (1.8%)	3 (0.2%)
HLA-B mismatch	35 (3.4%)	22 (2.0%)	24 (1.9%)	23 (1.8%)	3 (0.2%)
HLA-DR mismatch	37 (3.6%)	22 (2.0%)	24 (1.9%)	23 (1.8%)	3 (0.2%)
HLA-DQ mismatch	691 (66.4%)	582 (53.3%)	568 (45.2%)	538 (41.7%)	491 (37.3%)
Donor blood group	5 (0.5%)	13 (1.2%)	7 (0.6%)	0 (0.0%)	0 (0.0%)
Recipient blood group	5 (0.5%)	12 (1.1%)	7 (0.6%)	0 (0.0%)	0 (0.0%)
Maximum cytotoxic antibodies	59 (5.7%)	74 (6.8%)	90 (7.2%)	121 (9.4%)	241 (18.3%)
Current (At transplant) antibodies	74 (7.1%)	72 (6.6%)	79 (6.3%)	68 (5.3%)	44 (3.3%)

Table 16 Cause of graft failure

Variable	2014	2015	2016	2017	2018
Frequency	294	312	295	316	353
Cause of graft failure	0 (0.0%)	0 (0.0%)	7 (2.4%)	37 (11.7%)	21 (5.9%)

Table 17 Rejection data

Variable	2014	2015	2016	2017	2018
Frequency	469	480	426	538	461
Was a biopsy performed?	13 (2.8%)	9 (1.9%)	5 (1.2%)	2 (0.4%)	2 (0.4%)
Response of this rejection to treatment	19 (4.1%)	20 (4.2%)	21 (4.9%)	40 (7.4%)	54 (11.7%)
Primary treatment of rejection	6 (1.3%)	6 (1.3%)	13 (3.1%)	10 (1.9%)	16 (3.5%)

Table 18 Rejection data if biopsy performed

Variable	2014	2015	2016	2017	2018
Frequency	446	462	409	526	450
If biopsy is Yes ?Cellular	30 (6.7%)	5 (1.1%)	10 (2.4%)	14 (2.7%)	21 (4.7%)
If biopsy is Yes ?Glomerular	46 (10.3%)	9 (1.9%)	14 (3.4%)	14 (2.7%)	16 (3.6%)
If biopsy is Yes ?Vascular	43 (9.6%)	8 (1.7%)	18 (4.4%)	21 (4.0%)	20 (4.4%)
Humoral Rejection	53 (11.9%)	15 (3.2%)	20 (4.9%)	14 (2.7%)	22 (4.9%)
If biopsy is Yes and Banff g is known	66 (14.8%)	58 (12.6%)	60 (14.7%)	39 (7.4%)	34 (7.6%)
If biopsy is Yes and Banff i is known	66 (14.8%)	58 (12.6%)	55 (13.4%)	38 (7.2%)	34 (7.6%)
If biopsy is Yes and Banff t is known	65 (14.6%)	57 (12.3%)	55 (13.4%)	38 (7.2%)	32 (7.1%)
If biopsy is Yes and Banff v is known	67 (15.0%)	60 (13.0%)	62 (15.2%)	47 (8.9%)	38 (8.4%)

Table 19 Rejection data if biopsy not performed

Variable	2014	2015	2016	2017	2018
Frequency	10	9	12	10	9
Likelihood of rejection if biopsy not performed	0 (0.0%)	1 (11.1%)	1 (8.3%)	0 (0.0%)	0 (0.0%)

Transplant Follow Up Data

Table 20 Transplant follow-up data, 0 months

Variable	2014	2015	2016	2017	2018
Frequency	1062	1112	1277	1304	1342
Weight	68 (6.4%)	60 (5.4%)	133 (10.4%)	59 (4.5%)	61 (4.5%)
Drug data	38 (3.6%)	43 (3.9%)	119 (9.3%)	52 (4.0%)	66 (4.9%)

Table 21 Transplant follow-up data, 1 months

Variable	2014	2015	2016	2017	2018
Frequency	1037	1053	1264	1301	1321
Weight	58 (5.6%)	99 (9.4%)	136 (10.8%)	43 (3.3%)	57 (4.3%)
Serum creatinine	38 (3.7%)	45 (4.3%)	113 (8.9%)	41 (3.2%)	40 (3.0%)
Drug data	34 (3.3%)	38 (3.6%)	98 (7.8%)	27 (2.1%)	27 (2.0%)

Table 22 Transplant follow-up data, 2 months

Variable	2014	2015	2016	2017	2018
Frequency	1013	1060	1212	1306	1325
Weight	68 (6.7%)	114 (10.8%)	172 (14.2%)	80 (6.1%)	61 (4.6%)
Serum creatinine	43 (4.2%)	43 (4.1%)	129 (10.6%)	51 (3.9%)	41 (3.1%)
Drug data	37 (3.7%)	36 (3.4%)	116 (9.6%)	44 (3.4%)	30 (2.3%)

Table 23 Transplant follow-up data, 3 months

Variable	2014	2015	2016	2017	2018
Frequency	1020	1052	1189	1293	1303
Weight	83 (8.1%)	122 (11.6%)	168 (14.1%)	131 (10.1%)	92 (7.1%)
Serum creatinine	51 (5.0%)	44 (4.2%)	113 (9.5%)	79 (6.1%)	63 (4.8%)
Drug data	46 (4.5%)	37 (3.5%)	106 (8.9%)	71 (5.5%)	50 (3.8%)

Table 24 Transplant follow-up data, 6 months

Variable	2014	2015	2016	2017	2018
Frequency	985	985	1182	1268	1281
Weight	95 (9.6%)	145 (14.7%)	216 (18.3%)	189 (14.9%)	171 (13.3%)
Serum creatinine	50 (5.1%)	59 (6.0%)	139 (11.8%)	96 (7.6%)	126 (9.8%)
Drug data	47 (4.8%)	53 (5.4%)	138 (11.7%)	104 (8.2%)	114 (8.9%)

Table 25 Transplant follow-up data, 12 months

Variable	2014	2015	2016	2017	2018
Frequency	959	1006	1047	1215	1247
Weight	101 (10.5%)	137 (13.6%)	175 (16.7%)	146 (12.0%)	171 (13.7%)
Serum creatinine	32 (3.3%)	47 (4.7%)	118 (11.3%)	86 (7.1%)	129 (10.3%)
Drug data	34 (3.5%)	44 (4.4%)	106 (10.1%)	81 (6.7%)	123 (9.9%)

Table 26 Transplant follow-up data, 24 months

Variable	2014	2015	2016	2017	2018
Frequency	896	937	988	1014	1177
Weight	96 (10.7%)	114 (12.2%)	162 (16.4%)	132 (13.0%)	194 (16.5%)
Serum creatinine	27 (3.0%)	47 (5.0%)	88 (8.9%)	82 (8.1%)	148 (12.6%)
Drug data	33 (3.7%)	45 (4.8%)	85 (8.6%)	81 (8.0%)	139 (11.8%)

Table 27 Transplant follow-up data, 36 months

Variable	2014	2015	2016	2017	2018
Frequency	861	870	903	955	987
Weight	91 (10.6%)	115 (13.2%)	128 (14.2%)	150 (15.7%)	152 (15.4%)
Serum creatinine	36 (4.2%)	41 (4.7%)	80 (8.9%)	89 (9.3%)	116 (11.8%)
Drug data	40 (4.6%)	41 (4.7%)	79 (8.7%)	87 (9.1%)	116 (11.8%)

Table 28 Transplant follow-up data, 60 months

Variable	2014	2015	2016	2017	2018
Frequency	784	799	806	809	842
Weight	99 (12.6%)	127 (15.9%)	159 (19.7%)	137 (16.9%)	147 (17.5%)
Serum creatinine	35 (4.5%)	45 (5.6%)	97 (12.0%)	72 (8.9%)	108 (12.8%)
Drug data	42 (5.4%)	39 (4.9%)	87 (10.8%)	71 (8.8%)	107 (12.7%)

Table 29 Transplant follow-up data, 84 months

Variable	2014	2015	2016	2017	2018
Frequency	590	703	723	740	729
Weight	68 (11.5%)	90 (12.8%)	148 (20.5%)	124 (16.8%)	125 (17.1%)
Serum creatinine	20 (3.4%)	40 (5.7%)	96 (13.3%)	79 (10.7%)	95 (13.0%)
Drug data	24 (4.1%)	39 (5.5%)	84 (11.6%)	78 (10.5%)	98 (13.4%)

Table 30 Transplant follow-up data, 120 months

Variable	2014	2015	2016	2017	2018
Frequency	522	470	489	494	591
Weight	54 (10.3%)	57 (12.1%)	87 (17.8%)	72 (14.6%)	106 (17.9%)
Serum creatinine	14 (2.7%)	31 (6.6%)	51 (10.4%)	44 (8.9%)	69 (11.7%)
Drug data	4 (0.8%)	29 (6.2%)	43 (8.8%)	48 (9.7%)	72 (12.2%)

Table 31 Transplant follow-up data, 180 months

Variable	2014	2015	2016	2017	2018
Frequency	258	322	303	369	314
Weight	36 (14.0%)	45 (14.0%)	63 (20.8%)	51 (13.8%)	63 (20.1%)
Serum creatinine	13 (5.0%)	22 (6.8%)	42 (13.9%)	31 (8.4%)	46 (14.6%)
Drug data	11 (4.3%)	24 (7.5%)	40 (13.2%)	38 (10.3%)	48 (15.3%)

Table 32 Transplant follow-up data, 240 months

Variable	2014	2015	2016	2017	2018
Frequency	138	162	183	196	183
Weight	14 (10.1%)	25 (15.4%)	30 (16.4%)	36 (18.4%)	40 (21.9%)
Serum creatinine	7 (5.1%)	12 (7.4%)	19 (10.4%)	25 (12.8%)	30 (16.4%)
Drug data	6 (4.3%)	12 (7.4%)	21 (11.5%)	28 (14.3%)	30 (16.4%)

Table 33 Transplant follow-up data, 300 months

Variable	2014	2015	2016	2017	2018
Frequency	82	84	97	94	77
Weight	8 (9.8%)	14 (16.7%)	17 (17.5%)	18 (19.1%)	19 (24.7%)
Serum creatinine	3 (3.7%)	11 (13.1%)	9 (9.3%)	11 (11.7%)	11 (14.3%)
Drug data	3 (3.7%)	5 (6.0%)	8 (8.2%)	15 (16.0%)	12 (15.6%)

Table 34 Transplant follow-up data, 360 months

Variable	2014	2015	2016	2017	2018
Frequency	41	39	46	44	55
Weight	9 (22.0%)	9 (23.1%)	11 (23.9%)	8 (18.2%)	13 (23.6%)
Serum creatinine	4 (9.8%)	4 (10.3%)	7 (15.2%)	8 (18.2%)	8 (14.5%)
Drug data	4 (9.8%)	3 (7.7%)	8 (17.4%)	4 (9.1%)	8 (14.5%)

Table 35 Transplant follow-up data, 420 months

Variable	2014	2015	2016	2017	2018
Frequency	20	19	30	28	20
Weight	4 (20.0%)	5 (26.3%)	10 (33.3%)	7 (25.0%)	7 (35.0%)
Serum creatinine	2 (10.0%)	2 (10.5%)	6 (20.0%)	4 (14.3%)	3 (15.0%)
Drug data	4 (20.0%)	2 (10.5%)	6 (20.0%)	4 (14.3%)	3 (15.0%)

Table 36 Transplant follow-up data, 480 months

Variable	2014	2015	2016	2017	2018
Frequency	9	7	9	15	15
Weight	3 (33.3%)	1 (14.3%)	1 (11.1%)	2 (13.3%)	5 (33.3%)
Serum creatinine	2 (22.2%)	0 (0.0%)	0 (0.0%)	1 (6.7%)	3 (20.0%)
Drug data	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (20.0%)

Table 37 Transplant follow-up data, 540 months

Variable	2014	2015	2016	2017	2018
Frequency	2	5	6	0	2
Weight	1 (50.0%)	3 (60.0%)	2 (33.3%)	-	0 (0.0%)
Serum creatinine	0 (0.0%)	1 (20.0%)	2 (33.3%)	-	0 (0.0%)
Drug data	0 (0.0%)	1 (20.0%)	2 (33.3%)	-	0 (0.0%)

Table 38 Transplant follow-up data, 600 months

Variable	2014	2015	2016	2017	2018
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

Paediatric Data

Table 39 Paediatric assessment at entry

Variable	2014	2015	2016	2017	2018
Frequency	42	36	40	48	43
Height	2 (4.8%)	7 (19.4%)	16 (40.0%)	17 (35.4%)	6 (14.0%)
Weight	2 (4.8%)	7 (19.4%)	16 (40.0%)	17 (35.4%)	6 (14.0%)
Paediatric Assessment at end of each Survey	2 (4.8%)	9 (25.0%)	17 (42.5%)	16 (33.3%)	6 (14.0%)

Table 40 Paediatric assessment at survey

Variable	2014	2015	2016	2017	2018
Frequency	339	332	340	352	359
Height	31 (9.1%)	26 (7.8%)	24 (7.1%)	35 (9.9%)	29 (8.1%)
Weight	22 (6.5%)	21 (6.3%)	22 (6.5%)	35 (9.9%)	27 (7.5%)
Paediatric Assessment at end of each Survey	21 (6.2%)	24 (7.2%)	24 (7.1%)	33 (9.4%)	26 (7.2%)

Parenthood Data

Table 41 Parenthood data

Variable	2014	2015	2016	2017	2018
Frequency	70	74	52	59	45
Pregnancy outcome	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	4 (5.7%)	8 (10.8%)	13 (25.0%)	9 (15.3%)	8 (17.8%)
Gestational age (best clinical estimate, weeks)	70 (100.0%)	73 (98.6%)	51 (98.1%)	37 (62.7%)	15 (33.3%)
Diabetes	70 (100.0%)	74 (100.0%)	51 (98.1%)	29 (49.2%)	16 (35.6%)
Hypertension (Somanz 2014 definition)	70 (100.0%)	74 (100.0%)	51 (98.1%)	32 (54.2%)	24 (53.3%)
CYA Immunosuppression at conception	70 (100.0%)	74 (100.0%)	51 (98.1%)	36 (61.0%)	25 (55.6%)
AZA Immunosuppression at conception	70 (100.0%)	74 (100.0%)	51 (98.1%)	34 (57.6%)	22 (48.9%)
Pred Immunosuppression at conception	70 (100.0%)	74 (100.0%)	50 (96.2%)	34 (57.6%)	22 (48.9%)
Tac Immunosuppression at conception	70 (100.0%)	74 (100.0%)	50 (96.2%)	33 (55.9%)	22 (48.9%)
MMF Immunosuppression at conception	70 (100.0%)	74 (100.0%)	50 (96.2%)	35 (59.3%)	25 (55.6%)
Sirol Immunosuppression at conception	70 (100.0%)	74 (100.0%)	51 (98.1%)	36 (61.0%)	26 (57.8%)
Other Immunosuppression at conception	70 (100.0%)	74 (100.0%)	51 (98.1%)	37 (62.7%)	27 (60.0%)
Labour type	70 (100.0%)	74 (100.0%)	50 (96.2%)	37 (62.7%)	23 (51.1%)
Delivery type	70 (100.0%)	74 (100.0%)	51 (98.1%)	37 (62.7%)	24 (53.3%)
Congenital condition present?	70 (100.0%)	74 (100.0%)	50 (96.2%)	35 (59.3%)	16 (35.6%)

Table 42 Parenthood birthweight data

Variable	2014	2015	2016	2017	2018
Frequency	62	68	42	54	42
Weight at birth (gms)	15 (24.2%)	18 (26.5%)	8 (19.0%)	10 (18.5%)	6 (14.3%)

Table 43 Parenthood creatinine prior to conception

Variable	2014	2015	2016	2017	2018
Frequency	27	20	15	19	10
Creatinine prior to conception (umol/L)	2 (7.4%)	3 (15.0%)	2 (13.3%)	3 (15.8%)	1 (10.0%)

Table 44 Parenthood creatinine post delivery

Variable	2014	2015	2016	2017	2018
Frequency	27	19	15	19	8
Creatinine 3 months post delivery (umol/L)	4 (14.8%)	5 (26.3%)	2 (13.3%)	5 (26.3%)	2 (25.0%)

Cancer Data

Table 45 Non-skin cancer data

Variable	2014	2015	2016	2017	2018
Frequency	648	637	601	529	474
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	17 (2.6%)	14 (2.2%)	12 (2.0%)	11 (2.1%)	19 (4.0%)
Cancer staging code	21 (3.2%)	30 (4.7%)	34 (5.7%)	43 (8.1%)	54 (11.4%)
Type 1st treatment	16 (2.5%)	31 (4.9%)	35 (5.8%)	40 (7.6%)	66 (13.9%)